HomeProductsBioactive CompoundsCell CycleAurora KinaseTak-285
Chemical structure of CAS 871026-44-7

Tak-285

CAS No.871026-44-7
MDL No.MFCD22124520
MFC26H25ClF3N5O3
MW548.00
InChI KeyZYQXEVJIFYIBHZ-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.871026-44-7
Product NameTak-285

Biological Targets

EGFR·ERBB2

Associated Conditions

cancer
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Design and synthesis of pyrrolo[3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: exploration of novel back-pocket binders.

Journal of medicinal chemistry • Vol. 55, Issue 8 • 2012
PMID: 22439974DOI: 10.1021/jm300185p

Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients.

British journal of cancer • Vol. 106, Issue 4 • 2012
PMID: 22240796PMC: PMC3322948DOI: 10.1038/bjc.2011.590

Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats.

Brain research bulletin • Vol. 87, Issue 4-5 • 2012
PMID: 22245027DOI: 10.1016/j.brainresbull.2012.01.002

Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.

Journal of medicinal chemistry • Vol. 54, Issue 23 • 2011
PMID: 22003817DOI: 10.1021/jm2008634

Documentation